ClinicalTrials.gg
CompletedNCT02962284Updated Nov 19, 2021Results posted

One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™

A Phase 2 interventional study of abiraterone acetate with Methylprednisolone in Metastatic Prostate Cancer, sponsored by Sun Pharmaceutical Industries Limited. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
79th of 98
20 · median 56
Started
2016
with 6 others
Phase 2
59 of 98
9 open now
Registered
54th of 98
by date
Lead sponsor
3 of 98
Sun Pharmaceutical Industries Limited

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 79th largest by enrollment, is one of 7 that started in 2016, is one of 59 in phase 2, and was the 54th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, single-arm, multi-center extension study to evaluate safety in patients with mCRPC of YONSA 500 mg (4 x 125 mg qd) with methylprednisolone (4 mg bid). Patients will have successfully completed an 84-day treatment with abiraterone acetate in a previous trial. Results from the final visit of the previous study will be used to determine patient's eligibility for this study. Patients in this study will be eligible to receive open-label YONSA with methylprednisolone for up to 12 months. Pharmacodynamic parameters of serum testosterone and PSA levels will be monitored. Disease progression will be assessed by PCWG2 criteria.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successful completion of 84 days of treatment with YONSA in Churchill Pharmaceuticals clinical trial, CHL-AA-201
  • Last dose of YONSA or Zytiga within 45 days prior to treatment in this study
  • Written obtained prior to any study-related procedure being performed
  • Has in the investigator's opinion, the potential to gain clinical benefit with YONSA treatment
  • Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level \<50 ng/dL at screening
  • of at least 9 months at screening
  • Subject is willing and able to comply with all protocol requirements assessments
  • Agrees to protocol-defined use of effective .

Exclusion criteria

Exclusion Criteria:

  • Serious concurrent illness, including psychiatric illness, that would interfere with study participation
  • Inability to swallow tablets whole
  • Known to YONSA, methylprednisolone, or any in study medications
  • Moderate to severe hepatic impairment ( Classes B and C)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    YONSA with Methylprednisolone

    Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)

    Drug: abiraterone acetate with Methylprednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events

    Adverse events

    Time frame: one year

Secondary outcomes

  1. Proportion of Subjects With Disease Progression

    Number of participants who had disease progression

    Time frame: one year

  2. Testosterone Levels

    Change in serum testosterone levels from baseline

    Time frame: Baseline and 360 days

  3. Prostate Specific Antigen Levels

    Change in serum testosterone levels after one year of treatment against baseline

    Time frame: One year

  4. Testosterone Complete Suppression

    Proportion of subjects with complete suppression of testosterone levels

    Time frame: 360 days

  5. Percentage of Subjects With Prostate Specific Antigen - 50 Response

    A decrease of ≥50% reduction from baseline of the study CHL-AA-201

    Time frame: 360 days

07

Results

Posted Jul 22, 2019

Participant flow

A total of 20 subjects were enrolled in the study. Of these, 9 subjects were previously treated with YONSA and 11 subjects were previously treated with Zytiga in CHL-AA-201. Twelve (60.0%) subjects completed the study

Participant flow — Overall Study
MilestonePreceding Treatment - YonsaPreceding Treatment - Zytiga
Started911
Completed48
Not completed53
Withdrew: Death20
Withdrew: Progressive disease23
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Subjects With Adverse Events

Adverse events

Time frame:
one year
Reported as:
Number · Participants
Number of Subjects With Adverse Events
ParticipantsPreceding Treatment - YonsaPreceding Treatment - Zytiga
Number of Subjects With Adverse Events89
SecondaryProportion of Subjects With Disease Progression

Number of participants who had disease progression

Time frame:
one year
Reported as:
Count of participants · Participants
Proportion of Subjects With Disease Progression
ParticipantsPreceding Treatment - YonsaPreceding Treatment - Zytiga
Proportion of Subjects With Disease Progression13
Statistical analysis
  • Preceding Treatment - Yonsa vs Preceding Treatment - Zytiga · ANCOVA · p = >0.1
SecondaryTestosterone Levels

Change in serum testosterone levels from baseline

Time frame:
Baseline and 360 days
Reported as:
Mean · ng/dL
Testosterone Levels
ng/dLPreceding Treatment - YonsaPreceding Treatment - Zytiga
Testosterone Levels-6.24 ± 2.02-5.87 ± 3.64
SecondaryProstate Specific Antigen Levels

Change in serum testosterone levels after one year of treatment against baseline

Time frame:
One year
Reported as:
Mean · ng/dL
Prostate Specific Antigen Levels
ng/dLPreceding Treatment - YonsaPreceding Treatment - Zytiga
Prostate Specific Antigen Levels-60.12 ± 115.63-112.76 ± 239.85
SecondaryTestosterone Complete Suppression

Proportion of subjects with complete suppression of testosterone levels

Time frame:
360 days
Reported as:
Number · percentage of subjects
Testosterone Complete Suppression
percentage of subjectsPreceding Treatment - YonsaPreceding Treatment - Zytiga
Testosterone Complete Suppression10087.5
SecondaryPercentage of Subjects With Prostate Specific Antigen - 50 Response

A decrease of ≥50% reduction from baseline of the study CHL-AA-201

Time frame:
360 days
Reported as:
Number · percentage of number of subjects
Percentage of Subjects With Prostate Specific Antigen - 50 Response
percentage of number of subjectsPreceding Treatment - YonsaPreceding Treatment - Zytiga
Percentage of Subjects With Prostate Specific Antigen - 50 Response60.055.6

Adverse events

Collected over One year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Preceding Treatment - Yonsa2/9 (22.2%)3/9 (33.3%)8/9 (88.9%)
Preceding Treatment - Zytiga0/11 (0%)1/11 (9.1%)9/11 (81.8%)
Most frequent serious events
Most frequent serious events
EventPreceding Treatment - YonsaPreceding Treatment - Zytiga
Septic shockInfections and infestations1/90/11
Head injuryInjury, poisoning and procedural complications1/90/11
AbasiaGeneral disorders1/90/11
AstheniaGeneral disorders1/90/11
DehydrationMetabolism and nutrition disorders1/90/11
Non-cardiac chest painGeneral disorders1/90/11
Right leg cellulitisInfections and infestations0/91/11
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPreceding Treatment - YonsaPreceding Treatment - Zytiga
BronchitisInfections and infestations0/92/11
Iron deficiency anaemiaBlood and lymphatic system disorders1/90/11
NauseaGastrointestinal disorders1/90/11
VomitingGastrointestinal disorders1/90/11
AbasiaGeneral disorders1/90/11
AstheniaGeneral disorders1/90/11
Face oedemaGeneral disorders1/90/11
FatigueGeneral disorders1/91/11
MassGeneral disorders1/90/11
NoduleGeneral disorders1/90/11

Baseline characteristics

Age, Customized
Age, Customized(Participants)Preceding Treatment - YonsaPreceding Treatment - ZytigaTotal
<75 years459
≥75 years5611
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Preceding Treatment - YonsaPreceding Treatment - ZytigaTotal
Male91120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Preceding Treatment - YonsaPreceding Treatment - ZytigaTotal
Hispanic or Latino202
Not Hispanic or Latino71118
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We do not plan to make individual participant data available

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2018, 16 months.

Results were first posted in Jul 2019, 1 year 4 months after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 16 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2016
First posted
Nov 11, 2016
StartActual
Nov 2016
Primary completionActual
Mar 2018
CompletionActual
Jun 2018
Results first posted
Jul 22, 2019
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02962284
Responsible party
Sponsor
First posted
Nov 11, 2016
Start date
Nov 2016
Primary completion
Mar 2018
Completion
Jun 2018
Results posted
Jul 22, 2019
Last update
Nov 19, 2021

Study contacts

Paul Nemeth, Ph.D.
study director · Churchill Pharmaceuticals LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate · Methylprednisolone

Start the discussion